Institution
Uppsala University
Education•Uppsala, Sweden•
About: Uppsala University is a education organization based out in Uppsala, Sweden. It is known for research contribution in the topics: Population & Gene. The organization has 36485 authors who have published 107509 publications receiving 4220668 citations. The organization is also known as: Uppsala universitet & uu.se.
Topics: Population, Gene, Context (language use), Thin film, Receptor
Papers published on a yearly basis
Papers
More filters
TL;DR: The evidence for regulated expression of specific domains in HS chains and its relation to selective protein binding is outlined and the current information on HS biosynthesis is considered, with the aim of understanding the mechanisms in control of generating specific saccharide sequences.
692 citations
TL;DR: The CONVINCE trial did not demonstrate equivalence of a COER verapamil–based antihypertensive regimen compared with a regimen beginning with a diuretic or -blocker, and data indicate that the effectiveness of calcium-channel therapy in reducing cardiovascular disease is similar but not better than diuresis treatment.
Abstract: the HR was 1.15 (95% CI, 0.90-1.48); for fatal or nonfatal myocardial infarction, 0.82 (95% CI, 0.65-1.03); and for cardiovascular disease–related death, 1.09 (95% CI, 0.87-1.37). The HR was 1.05 (95% CI, 0.95-1.16) for any prespecified cardiovascular disease–related event and 1.08 (95% CI, 0.93-1.26) for all-cause mortality. Nonstroke hemorrhage was more common with participants in the COER-verapamil group (n=118) compared with the atenolol or hydrochlorothiazide group (n=79) (HR, 1.54 [95% CI, 1.16-2.04]; P=.003). More cardiovascular disease–related events occurred between 6 AM and noon in both the COER verapamil (99/277) and atenolol or hydrochlorothiazide (88/274) groups; HR, 1.15 (95% CI, 0.86-1.53). Conclusions The CONVINCE trial did not demonstrate equivalence of a COER verapamil–based antihypertensive regimen compared with a regimen beginning with a diuretic or -blocker. When considered in the context of other trials of calcium antagonists, these data indicate that the effectiveness of calcium-channel therapy in reducing cardiovascular disease is similar but not better than diuretic or -blocker treatment. JAMA. 2003;289:2073-2082 www.jama.com
691 citations
Duke University1, Uppsala University2, University of Kentucky3, University of Alberta4, Katholieke Universiteit Leuven5, Auckland City Hospital6, Flinders University7, Merck & Co.8, University of Tennessee Health Science Center9, University of Perugia10, University of Freiburg11, University of Barcelona12, Ufuk University13, Henry Ford Health System14, Peking Union Medical College15, Leiden University16, Cleveland Clinic17, Pierre-and-Marie-Curie University18, University of São Paulo19, Kumamoto University20, University of Basel21, University of Chile22, University of Sheffield23, University of Ferrara24, Thomas Jefferson University25, Charles University in Prague26
TL;DR: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage.
Abstract: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.).
690 citations
TL;DR: The ligand 3-N-[11C]methylspiperone, which preferentially binds to dopamine receptors in vivo, was used to image the receptors by positron emission tomography scanning in baboons and in humans, and holds promise for noninvasive clinical studies of dopamine receptor in humans.
Abstract: Neurotransmitter receptors may be involved in a number of neuropsychiatric disease states. The ligand 3-N-[11C]methylspiperone, which preferentially binds to dopamine receptors in vivo, was used to image the receptors by positron emission tomography scanning in baboons and in humans. This technique holds promise for noninvasive clinical studies of dopamine receptors in humans.
689 citations
TL;DR: A review of recent advances in the use of Sn or Si-based electrodes together with the remaining challenges to be addressed and issues to be solved prior to such electrodes being commercially implemented in Li-ion cells is presented in this paper.
Abstract: In the race for better Li-ion batteries, research on anode materials is very intensive as there is a strong desire to find alternatives to carbonaceous negative electrodes. A large part of these studies is devoted to alloying reactions, which have been known for more than thirty years but that have regained great interest by downsizing particle sizes, moving to nano-textured/nanostructured composites, or designing new electrode concepts. It is not the scope of this review to retrace twenty-five years of research, but rather to highlight recent advances that have been made in the use of Sn or Si-based electrodes together with the remaining challenges to be addressed and issues to be solved prior to such electrodes being commercially implemented in Li-ion cells.
689 citations
Authors
Showing all 36854 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Zhong Lin Wang | 245 | 2529 | 259003 |
| Lewis C. Cantley | 196 | 748 | 169037 |
| Darien Wood | 160 | 2174 | 136596 |
| Kaj Blennow | 160 | 1845 | 116237 |
| Christopher J. O'Donnell | 159 | 869 | 126278 |
| Tomas Hökfelt | 158 | 1033 | 95979 |
| Peter G. Schultz | 156 | 893 | 89716 |
| Frederik Barkhof | 154 | 1449 | 104982 |
| Deepak L. Bhatt | 149 | 1973 | 114652 |
| Svante Pääbo | 147 | 407 | 84489 |
| Jan-Åke Gustafsson | 147 | 1058 | 98804 |
| Hans-Olov Adami | 145 | 908 | 83473 |
| Hermann Kolanoski | 145 | 1279 | 96152 |
| Kjell Fuxe | 142 | 1479 | 89846 |
| Jan Conrad | 141 | 826 | 71445 |